SCHEMBL1785138

SCHEMBL1785138

CNc1nc2ccc(-c3nn(C(C)C)c4ncnc(N)c34)cc2s1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SRC P12931 17/20 0.62
ABL1 P00519 16/20 0.62
MTOR P42345 15/20 0.62
PIK3CD O00329 15/20 0.62
PIK3CA P42336 15/20 0.62
PIK3CB P42338 15/20 0.62
PIK3CG P48736 15/20 0.62
PRKDC P78527 14/20 0.62
HCK P08631 14/20 0.62
EGFR P00533 13/20 0.62
KDR P35968 13/20 0.62
EPHB4 P54760 13/20 0.62
PI4KB Q9UBF8 5/20 0.61
BACE1 P56817 1/20 0.61
RICTOR Q6R327 1/20 0.58
RPTOR Q8N122 1/20 0.58
PIK3C3 Q8NEB9 1/20 0.58
MAPKAP1 Q9BPZ7 1/20 0.58
MLST8 Q9BVC4 1/20 0.58
BMPR1B O00238 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21082545 0.92 SRC (0.62) SRCABL1MTORPIK3CDPIK3CA
SCHEMBL8008773 0.89 SRC (0.59) SRCABL1MTORPIK3CDPIK3CA
SCHEMBL8006833 0.88 KDR (0.56) SRCABL1MTORPIK3CDPIK3CA
SCHEMBL1787523 0.88 PIK3CD (0.62) SRCABL1MTORPIK3CDPIK3CA
SCHEMBL7997108 0.88 SRC (0.57) SRCABL1MTORPIK3CDPIK3CA
SCHEMBL12607034 0.88 SRC (0.67) SRCABL1MTORPIK3CDPIK3CA
SCHEMBL8012348 0.87 SRC (0.56) SRCABL1MTORPIK3CDPIK3CA
SCHEMBL8012344 0.87 PIK3CD (0.56) SRCABL1MTORPIK3CDPIK3CA
SCHEMBL16601548 0.87 SRC (0.67) SRCABL1MTORPIK3CDPIK3CA
SCHEMBL8006218 0.85 SRC (0.55) SRCABL1MTORPIK3CDPIK3CA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9828378-B2 Kinase inhibitors and methods of use INTELLIKINE LLC (US) 2017-11-28 US disclosed
US-9637492-B2 Benzothiazole kinase inhibitors and methods of use INTELLIKINE LLC (US) 2017-05-02 US disclosed
US-9637492-B2 Benzothiazole kinase inhibitors and methods of use INTELLIKINE LLC (US) 2017-05-02 US disclosed
EP-3009436-A1 KINASE INHIBITORS AND METHODS OF USE Intellikine, LLC (US) 2016-04-20 EP disclosed
US-20160024099-A1 KINASE INHIBITORS AND METHODS OF USE INTELLIKINE LLC 2016-01-28 US disclosed
EP-2313414-B1 KINASE INHIBITORS AND METHODS OF USE INTELLIKINE LLC (US) 2015-11-04 EP disclosed
US-20150225407-A1 Benzothiazole Kinase Inhibitors and Methods of Use INTELLIKINE LLC 2015-08-13 US disclosed
US-20150225407-A1 Benzothiazole Kinase Inhibitors and Methods of Use INTELLIKINE LLC 2015-08-13 US disclosed
US-9096611-B2 Kinase inhibitors and methods of use INTELLIKINE LLC (US) 2015-08-04 US disclosed
US-8993580-B2 Benzothiazole kinase inhibitors and methods of use INTELLIKINE LLC (US) 2015-03-31 US disclosed
US-8993580-B2 Benzothiazole kinase inhibitors and methods of use INTELLIKINE LLC (US) 2015-03-31 US disclosed
US-20110172228-A1 KINASE INHIBITORS AND METHODS OF USE INTELLIKINE LLC 2011-07-14 US disclosed
US-20110124641-A1 BENZOTHIAZOLE KINASE INHIBITORS AND METHODS OF USE INTELLIKINE LLC 2011-05-26 US disclosed
US-20110124641-A1 BENZOTHIAZOLE KINASE INHIBITORS AND METHODS OF USE INTELLIKINE LLC 2011-05-26 US disclosed
WO-2010006086-A2 KINASE INHIBITORS AND METHODS OF USE INTELLIKINE, INC. (US) 2010-01-14 WO disclosed
WO-2009114874-A2 BENZOTHIAZOLE KINASE INHIBITORS AND METHODS OF USE INTELLIKINE, INC. (US) 2009-09-17 WO disclosed
WO-2009114874-A2 BENZOTHIAZOLE KINASE INHIBITORS AND METHODS OF USE INTELLIKINE, INC. (US) 2009-09-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110172228-A1 KINASE INHIBITORS AND METHODS OF USE PIK3CA, MTOR, PDPK1 SRC 54/4885ABL1 73/4885MTOR 2/4885
US-20110124641-A1 BENZOTHIAZOLE KINASE INHIBITORS AND METHODS OF USE MTOR, PDPK1, PIKFYVE SRC 164/4885ABL1 93/4885MTOR 1/4885
US-20150225407-A1 Benzothiazole Kinase Inhibitors and Methods of Use MTOR, PDPK1, PIKFYVE SRC 164/4885ABL1 93/4885MTOR 1/4885
US-20160024099-A1 KINASE INHIBITORS AND METHODS OF USE PIK3CA, MTOR, PDPK1 SRC 54/4885ABL1 73/4885MTOR 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.